CytomX Therapeutics (NASDAQ:CTMX) Price Target Raised to $11.00

CytomX Therapeutics (NASDAQ:CTMX) had its price objective raised by equities researchers at Wedbush from $6.00 to $11.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Wedbush’s price target would suggest a potential upside of 62.96% from the stock’s current price.

Several other equities research analysts have also weighed in on the company. Guggenheim reiterated a “buy” rating and issued a $10.00 price objective on shares of CytomX Therapeutics in a research note on Monday, March 9th. Oppenheimer restated an “outperform” rating and set a $12.00 target price on shares of CytomX Therapeutics in a research report on Monday. Piper Sandler upped their price target on CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. HC Wainwright increased their price objective on CytomX Therapeutics from $10.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday. Finally, JPMorgan Chase & Co. raised CytomX Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $7.00 to $12.00 in a report on Monday. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $11.50.

CytomX Therapeutics Stock Performance

NASDAQ:CTMX opened at $6.75 on Tuesday. The company has a 50-day moving average of $5.24 and a 200-day moving average of $4.07. CytomX Therapeutics has a 52 week low of $0.40 and a 52 week high of $8.21. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of 16.88 and a beta of 2.44.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The business had revenue of $0.66 million during the quarter, compared to analyst estimates of $7.33 million. CytomX Therapeutics had a return on equity of 44.49% and a net margin of 24.66%. Sell-side analysts forecast that CytomX Therapeutics will post -0.05 EPS for the current year.

Institutional Investors Weigh In On CytomX Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC increased its position in CytomX Therapeutics by 4.5% in the 4th quarter. Squarepoint Ops LLC now owns 49,897 shares of the biotechnology company’s stock valued at $213,000 after acquiring an additional 2,169 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of CytomX Therapeutics by 83.2% during the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,000 shares in the last quarter. Velan Capital Investment Management LP lifted its position in shares of CytomX Therapeutics by 6.7% during the third quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biotechnology company’s stock worth $255,000 after purchasing an additional 5,000 shares in the last quarter. Farther Finance Advisors LLC bought a new stake in shares of CytomX Therapeutics during the third quarter valued at approximately $25,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of CytomX Therapeutics in the fourth quarter valued at approximately $35,000. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics News Roundup

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase 1 dose‑expansion data for Varsetatug (Varseta‑M) showed dose response with confirmed response rates of 32% at 10 mg/kg Q3W and 20% at 8.6 mg/kg Q3W, estimated PFS ~7.1 months at the higher dose, and a manageable safety profile—findings the company says support mid‑year FDA interactions to align on a potential registrational trial. Varsetatug Masetecan Positive Data Release
• Positive Sentiment: Market and media coverage amplified the data’s impact, highlighting response rates and estimated PFS that catalyzed the intraday rally as investors price in Varseta‑M’s late‑line CRC potential. Stock Market Today: CytomX Surges After Positive Data
• Positive Sentiment: Wall Street turned more bullish: JPMorgan upgraded CTMX to overweight with a $12 PT and HC Wainwright raised its PT to $17 (buy). A Seeking Alpha upgrade and note model a high risk‑adjusted NPV tied to Varseta‑M, supporting upside expectations if registrational plans advance. Seeking Alpha Upgrade & Analysis
• Neutral Sentiment: Pipeline development updates: CytomX is initiating combination studies (bevacizumab combo underway; chemo combo planned by end‑2026) and is seeking FDA alignment—progressive but timing and registrational design remain uncertain. 2025 Results and Business Update
• Negative Sentiment: CytomX launched a proposed underwritten public offering of $250M of common stock (and pre‑funded warrants for certain investors), which can provide runway but also raises near‑term dilution risk—a key watch for holders. Proposed Public Offering Announcement
• Negative Sentiment: Q4 results missed expectations: CTMX reported a larger‑than‑expected loss (EPS miss) and revenues well below estimates, which contrasts with the clinical upside and could pressure sentiment if funding/dilution concerns intensify. Zacks: Q4 Loss and Revenue Miss

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.